-
公开(公告)号：US20210261675A1
公开(公告)日：2021-08-26
申请号：US17164125
申请日：2021-02-01
发明人： Xiaohu FAN , Chuan-Chu CHOU , Qiuchuan ZHUANG , Pingyan WANG , Lin WANG , Lei YANG , Jiaying HAO
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/17 , C12N5/0783 , C07K19/00 , C12N5/10 , C12N15/62 , C12N15/63
摘要： The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US10934363B2
公开(公告)日：2021-03-02
申请号：US15751609
申请日：2016-08-10
发明人： Xiaohu Fan , Chuan-Chu Chou , Qiuchuan Zhuang , Pingyan Wang , Lin Wang , Lei Yang , Jiaying Hao
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/17 , C12N5/0783 , C07K19/00 , C12N5/10 , C12N15/62 , C12N15/63
摘要： The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US20240358754A1
公开(公告)日：2024-10-31
申请号：US18592234
申请日：2024-02-29
发明人： Nitin PATEL , Lida PACAUD , Yuhong QIU , Nikoletta LENDVAI , William DERAEDT , Jordan Mark SCHECTER , Ana Rute DE ASCENSAO SLAUGHTER , Carolina LONARDI
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61K45/06 , A61P35/00 , C07K16/2878 , A61K2239/13 , A61K2239/21 , A61K2239/22 , A61K2239/38 , A61K2239/48
摘要： Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
-
公开(公告)号：US20230270786A1
公开(公告)日：2023-08-31
申请号：US18175347
申请日：2023-02-27
发明人： Xiaohu FAN , Jordan SCHECTER , Lida PACAUD , Michael HIRSCHMANN
IPC分类号： A61K35/17 , A61K31/675 , A61K31/52 , A61K45/06 , A61P35/00
CPC分类号： A61K35/17 , A61K31/675 , A61K31/52 , A61K45/06 , A61P35/00
摘要： Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.
-
5.发明申请公开(公告)号：US20230061503A1
公开(公告)日：2023-03-02
申请号：US17740665
申请日：2022-05-10
发明人： Muhammad S. AKRAM , Kevin C. De Braganca , Jenna Goldberg , Carolyn Chang Jackson , Erin C. Lee , Nikoletta Lendvai , Maria Marquez de Mondelo , Yunsi Olyslager , Jun Qiu , Enrique Zudaire Ubani , Jean Xu
IPC分类号： A61K35/17 , A61P35/00 , A61K31/573 , A61K45/06 , G01N33/68
摘要： The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.
-
公开(公告)号：US20220127371A1
公开(公告)日：2022-04-28
申请号：US17518123
申请日：2021-11-03
发明人： Xiaohu FAN , Qiuchuan ZHUANG , Pingyan WANG , Lin WANG , Lei YANG , Jiaying HAO , Dan ZHAO , Xian HE
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/17 , C12N5/0783 , C07K19/00 , C12N5/10 , C12N15/62 , C12N15/63
摘要： The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US11186647B2
公开(公告)日：2021-11-30
申请号：US17168100
申请日：2021-02-04
发明人： Xiaohu Fan , Qiuchuan Zhuang , Pingyan Wang , Lin Wang , Lei Yang , Jiaying Hao
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/17 , C12N5/0783 , C07K19/00 , C12N5/10 , C12N15/62 , C12N15/63
摘要： The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US20210163615A1
公开(公告)日：2021-06-03
申请号：US17168100
申请日：2021-02-04
发明人： Xiaohu FAN , Qiuchuan ZHUANG , Pingyan WANG , Lin WANG , Lei YANG , Jiaying HAO , Dan ZHAO , Xian HE
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/17 , C12N5/0783 , C07K19/00 , C12N5/10 , C12N15/62 , C12N15/63
摘要： The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
公开(公告)号：US20240156962A1
公开(公告)日：2024-05-16
申请号：US18499720
申请日：2023-11-01
发明人： Lida PACAUD , Muhammad AKRAM , Dong GENG , Jordan SCHECTER , Carolyn Chang JACKSON , Enrique ZUDAIRE UBANI , Deepu MADDURI
IPC分类号： A61K39/00 , A61P35/00 , C12Q1/6886
CPC分类号： A61K39/464417 , A61K39/4611 , A61K39/4631 , A61P35/00 , C12Q1/6886 , A61K2239/38 , A61K2239/48 , C12Q2600/106 , C12Q2600/118
摘要： A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.
-
公开(公告)号：US20200078399A1
公开(公告)日：2020-03-12
申请号：US16303587
申请日：2017-08-10
发明人： Xiaohu FAN , Qiuchuan ZHUANG , Pingyan WANG , Lin WANG , Lei YANG , Jiaying HAO , Dan ZHAO , Xian HE
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K19/00 , C12N15/62 , C12N15/63 , C12N5/0783
摘要： Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.029 秒)
